Neuroventi announces the current status of brain disease-related drug development at BIO KOREA 2021.

21-06-10

Neuroventi participated in 'BIO KOREA 2021' held at COEX, Seoul from June 9 (Wednesday) to 11 (Friday) to inform the development status of treatments related to brain diseases.

Neuroventi, a bio-venture company, is a global leader leading the development of protection and treatment for brain development disorders, and a business portfolio covering overall brain diseases as well as prevention and treatment of brain development disorders such as autism spectrum disorder and attention deficit hyperactivity disorder. and is working with customers through research and product development.

Autism spectrum disorder is characterized by various accompanying symptoms such as lack of sociability, repetitive behavior, epilepsy, anxiety, and depression. Neuroventi develops a treatment that suppresses these symptoms and excitatory nerve activity.

In addition, existing treatments for ADHD have three major side effects, such as dependence, growth inhibition, and sleep disturbance, and while suppressing these, efforts are also being made to develop a treatment as a mechanism that suppresses the ADHD treatment target, dopamine, norepinephrine, and serotonin transporters.

Gyu-Seok Cho, director of Neuroventi, said, "In addition to the development of treatments for brain diseases, our company also serves as a CRO that provides preclinical efficacy evaluation services for overall brain diseases by possessing an HTS-based natural product treatment search system and cell and animal models for various brain diseases. ." he said.

Meanwhile, the theme of 'Bio Korea 2021' hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do is 'New Normal: Bio Innovation and Overcoming Limitations', and the direction and strategy for the health industry in Korea will be presented through conferences, exhibitions, and business forums. There will be a place to check it out. In addition, it is held both online and offline to share the latest issues and cutting-edge technologies in the biohealth market with investors from around the world, executives in the bio industry, and related researchers.